Table 2.
Tumour characteristics*
| Characteristic | Total (n (%)) | 2019 (n (%)) | 2020 (n (%)) |
|---|---|---|---|
| Location | 528 (100) | 250 (100) | 278 (100) |
| – Sinonasal | 5 (1) | 1 (0) | 4 (1) |
| – Nasopharyngeal | 17 (3) | 10 (4) | 7 (3) |
| – Oral | 148 (28) | 56 (22) | 92 (33) |
| – Oropharyngeal | 156 (30) | 77 (31) | 79 (28) |
| – Hypopharyngeal | 42 (8) | 22 (9) | 20 (7) |
| – Laryngeal | 124 (23) | 72 (29) | 52 (19) |
| – Salivary gland | 18 (3) | 8 (3) | 10 (4) |
| – Cancer of unknown primary | 18 (3) | 4 (2) | 14 (5) |
| Tumour–node–metastasis stage | |||
| – Tumour | 524 (100) | 250 (100) | 274 (100) |
| – TX | 16 (3) | 4 (2) | 12 (4) |
| – T1 | 112 (21) | 60 (24) | 52 (19) |
| – T2 | 115 (22) | 65 (26) | 50 (18) |
| – T3 | 112 (21) | 47 (19) | 65 (24) |
| – T4a | 150 (29) | 66 (26) | 84 (31) |
| – T4b | 19 (4) | 8 (3) | 11 (4) |
| Node | 526 (100) | 250 (100) | 276 (100) |
| – N0 | 243 (46) | 127 (51) | 116 (42) |
| – N1 | 119 (23) | 59 (24) | 60 (22) |
| – N2 | 120 (23) | 52 (21) | 68 (25) |
| – N3 | 44 (8) | 12 (5) | 32 (12) |
| Metastasis | 526 (100) | 250 (100) | 276 (100) |
| – M0 | 504 (96) | 239 (96) | 265 (96) |
| – M1 | 22 (4) | 11 (4) | 11 (4) |
| American Joint Committee on Cancer stage | 526 (100) | 250 (100) | 276 (100) |
| – I | 126 (24) | 71 (28) | 55 (20) |
| – II | 68 (13) | 36 (14) | 32 (12) |
| – III | 109 (21) | 50 (20) | 59 (21) |
| – IVa† | 159 (30) | 72 (29) | 87 (32) |
| – IVb | 48 (9) | 16 (6) | 32 (12) |
| – IVc | 16 (3) | 5 (2) | 11 (4) |
*
Numbers do not add to 100 per cent because of rounding; †human papilloma virus positive oropharyngeal cancers stage IV are equated to IVa for summary